The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has issued a positive opinion for the approval of Boehringer Ingelheim’s Giotrif (afatinib) for the treatment of patients with advanced squamous cell carcinoma of the lung whose disease has progressed on or after treatment with platinum-based chemotherapy. Afatinib is already approved for the treatment of patients with EGFR mutated non-small cell lung cancer (NSCLC).

Afatinib is already approved in over 60 countries for the first-line treatment of EGFR mutation-positive NSCLC.

Source: Boehringer Ingelheim